Common Side Effects of Opzelura
Opzelura (ruxolitinib cream) most often causes skin reactions at the application site. These include acne, redness, itching, and crusting, affecting more than 10% of patients in clinical trials. Headaches occur in about 5-10% of users.[1][2]
Serious Side Effects and Warnings
Serious risks are less common but require immediate medical attention:
- Infections: Increased chance of shingles (herpes zoster), urinary tract infections, or nasal infections due to immune suppression. One death from disseminated varicella zoster occurred in trials.[1]
- Cancer risk: Long-term use may raise chances of skin cancer or lymphoma, based on oral ruxolitinib data; monitor skin regularly.[2]
- Eye problems: Potential cataracts or glaucoma; get eye exams before and during treatment.[1]
- Blood clots or cardiovascular issues: Rare but reported in broader ruxolitinib use.[2]
FDA black box warning applies: Opzelura suppresses the immune system, raising infection risk. Avoid live vaccines and report fever, chills, or unusual fatigue.[1]
Side Effects in Specific Patient Groups
- Children (12+ for atopic dermatitis): Similar profile to adults, but acne and application-site reactions hit 20-25%. Not studied under 12.[2]
- Pregnancy/breastfeeding: May harm fetus (Category not assigned); use contraception. Unknown in breast milk—pump and discard during treatment.[1]
How Side Effects Compare Across Conditions
Opzelura treats atopic dermatitis and nonsegmental vitiligo. Trials show higher application-site reactions in vitiligo (up to 25%) vs. dermatitis (10-15%), possibly due to larger treated areas. Systemic effects like infections remain comparable.[2][3]
Managing and Reporting Side Effects
Stop use if serious infection or allergic reaction (hives, swelling, trouble breathing) occurs. Wash hands after applying; avoid eyes/mouth. Report to FDA via MedWatch or 1-800-FDA-1088. Most skin reactions improve over time or with moisturizers.[1]
[1]: FDA Prescribing Information for Opzelura (https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/215309s000lbl.pdf)
[2]: Opzelura.com Safety Information (https://www.opzelura.com/safety)
[3]: ClinicalTrials.gov Studies NCT03745651 and NCT04052425 (https://clinicaltrials.gov)